Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Jun 2020 17:40

RNS Number : 5914P
Open Orphan PLC
10 June 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Open Orphan Plc

 

Queen Mary BioEnterprises Innovation Centre

42 New Road

London

E1 2AX

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Acacia Research Corporation

City and country of registered office (if applicable)

Irvine, California, United States of America

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09/06/2020

6. Date on which issuer notified (DD/MM/YYYY):

10/06/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

2.29%

2.29%

593,535,138

Position of previous notification (if

applicable)

6.51%

6.51%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares of £0.001

GB00B9275X97

13,618,608

2.29%

SUBTOTAL 8. A

13,618,608

2.29%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Acacia Research

Corporation

2.29%

2.29%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

New York, New York, USA

Date of completion

09/06/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLBLGDLLDBDGGG
Date   Source Headline
25th Oct 20227:00 amRNSChange of name to hVIVO plc effective
20th Oct 20227:00 amRNSCapital Markets Day
18th Oct 20227:00 amRNSCFO appointment & change of Board roles
30th Sep 20227:00 amRNSPositive in vitro results for FLU-v published
29th Sep 20229:30 amRNSDirector dealings
27th Sep 20227:00 amRNSUpcoming Scientific Presentations
15th Sep 20227:00 amRNSComment regarding press speculation
8th Sep 20227:01 amRNSInterim results and trading update
8th Sep 20227:00 amRNSIntention to change name to hVIVO plc
1st Sep 20227:20 amRNSCAP accreditation
25th Aug 20227:00 amRNSNotice of results
22nd Aug 20227:00 amRNS£10.4m contract with existing Big Pharma client
4th Aug 20227:00 amRNS£6.2m Influenza human challenge study contract
5th Jul 20221:17 pmRNSResult of AGM
30th Jun 20227:00 amRNSOmicron human challenge model
14th Jun 20227:00 amRNS£7.2m RSV human challenge study contract
10th Jun 202212:13 pmRNSBoard appointment amendment
10th Jun 202212:00 pmRNSAnnual Report and Notice of AGM
8th Jun 20227:00 amRNSBoard appointment
7th Jun 20229:05 amRNSSecond Price Monitoring Extn
7th Jun 20229:00 amRNSPrice Monitoring Extension
7th Jun 20227:00 amRNSFinal results
1st Jun 20227:00 amRNSGBP14.7m influenza contract signed
26th May 20227:00 amRNSCompletion of Nominated Adviser due diligence
24th May 20227:00 amRNSNotice of results
18th May 20227:00 amRNS£7.3m Influenza human challenge study contract win
12th May 20227:00 amRNSWellcome publication
5th May 20227:00 amRNSVaccine field study contract
4th May 20227:00 amRNSChallenge virus manufacturing contract
4th May 20227:00 amRNSComment re: speculation
28th Apr 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
13th Apr 20227:00 amRNSProposal to Distribution in Specie Shareholders
12th Apr 202212:00 pmRNSPresentation at World Vaccine Congress
6th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:05 pmRNSSecond Price Monitoring Extn
6th Apr 20222:01 pmRNSPrice Monitoring Extension
6th Apr 202211:05 amRNSSecond Price Monitoring Extn
6th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 202210:05 amRNSCharacterisation Study results in Nature Medicine
25th Mar 20227:00 amRNS£5m RSV human challenge study contract win
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:37 pmRNSPrice Monitoring Extension
8th Mar 20227:00 amRNSTrading Update and screening facilities expansion
7th Mar 20222:06 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 202211:06 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSInvestor Presentations
24th Feb 20227:00 amRNSCEO Appointment
22nd Feb 20227:00 amRNSFDA Breakthrough Designation for Big Pharma RSV

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.